|Bid||9.55 x 3200|
|Ask||12.00 x 800|
|Day's Range||11.30 - 11.95|
|52 Week Range||3.20 - 12.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.32|
The first subject has been dosed in a clinical trial of AB-506, Arbutus’ second-generation capsid inhibitor. The regulatory filing for AB-452, Arbutus’ novel and proprietary RNA destabilizer, is on track for submission in Q3, with subject dosing to follow in Q4. Study completion is expected by Q3 2019.
Arbutus Biopharma Corp (NASDAQ: ABUS ) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally. The Analyst B. Riley FBR's ...
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day on July 10, 2018, at 4:00 p.m. ET. A live webcast will be available via the Investors section, under Events and Presentations of Arbutus' website at www.arbutusbio.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. Roivant Pipeline Day will be held on Tuesday, July 10, 2018, in New York City.
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of David Hastings as Chief Financial Officer, effective June 11, 2018. Mr. Hastings will assume the CFO role from Koert VandenEnden, Arbutus' interim Chief Financial Officer. "We’re excited to welcome David Hastings to Arbutus as our new CFO," said Dr. Mark J Murray, CEO of Arbutus.
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Diodes ...
LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has inked an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to exon 20 and certain methods of use of poziotinib. Active-Investors.com is currently working on the research report for Arbutus Biopharma Corporation (NASDAQ: ABUS), which also belongs to the Healthcare sector as the Company Spectrum Pharma.
The Burnaby, British Columbia-based company said it had a loss of 36 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Two Novel HBV Candidates Planned to Enter Clinical Development in 2018 GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA ...
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that it will hold a ...
While Wedbush predicts Arbutus Biopharma Corp (NASDAQ: ABUS ) shares will appreciate over the next six-to-12 months amid clinical data readouts, the sell-side firm stepped to the sidelines following the ...
Arbutus Biopharma Corporation’s (NASDAQ:ABUS): Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in CanadaRead More...